SE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTIO

IDIVAL Instituto de Investigación Sanitaria Valdecilla0 个研究点目标入组 200 人开始时间: 2020年5月8日最近更新: 2020年11月16日

适应症

试验速览

暂无简介。

•- Patients admitted to hospital with Covid-19, confirmed by microbiological tests or compatible clinical manifestations, with exclusion of other infections.
•- Age: 18-85 years old.
•- Time of evolution: more than 7 days since the beginning of symptoms.
•- Evidence of inflammation, defined by: Lung infiltrates + Gas exchange disturbance: PaO2 < 65 or Sat<93% (breathing air), or PAFI <300, or SAFI <440, or BCRSS =2 + Elevated biomarkers: PCR >15, or DD>800, or Ferritin >1000, or IL6>20
•- Absence of bacterial infection or other disease that explains the lung disorder.
•- Verbal informed consent, which will be recorded in history.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 120
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 80

•- Refusal to participate
•- Pregnancy
•- Established indication for mechanical ventilation, non-invasive ventilation or ICU admission
•- Immunosuppression
•- Chronic renal failure on dialysis

发起方

IDIVAL Instituto de Investigación Sanitaria Valdecilla